TGF-β signaling: Positive and negative effects on tumorigenesis

Current Opinion in Genetics and Development

Volumn 12, Issue 1, 2002, Pages 22-29

  Wakefield, Lalage M ^a   Roberts, Anita B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME; RAS PROTEIN; SMAD PROTEIN; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UBIQUITIN;

ALLELE; BREAST CARCINOMA; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CELL SURFACE; CELL TYPE; COLON CARCINOMA; ENZYME REPRESSION; HUMAN; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0036467496     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(01)00259-3     Document Type: Review

References (63)

1. Role of transforming growth factor-beta signaling in cancer
2. TGF-beta signaling in mammary gland development and tumorigenesis
3. TGFbeta signaling in growth control, cancer, and heritable disorders
4. Transforming growth factor beta 1 suppression of c-myc gene transcription: Role in inhibition of keratinocyte proliferation
5. Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program
6. Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta
7. Role of Smad proteins and transcription factor Sp1 in p21(WAF1/Cip1) regulation by transforming growth factor-beta
8. TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b
9. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta-induced cell-cycle arrest
10. Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor beta-related signaling
11. Transforming growth factor-beta-induced growth inhibition in a Smad4 mutant colon adenoma cell line
12. TGFbeta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation
13. The MEK pathway is required for stimulation of p21(WAF1/CIP1) by transforming growth factor-beta
14. 1 arrest
15. Transforming growth factor beta 1 suppresses genomic instability independent of a G1 arrest, p53, and Rb
16. Autocrine transforming growth factor beta suppresses telomerase activity and transcription of human telomerase reverse transcriptase in human cancer cells
17. Defects in TGF-beta signaling overcomes senescence of mouse keratinocytes expressing v-Ha-ras
18. Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis
19. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis
20. Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency
21. Association between the T29→C polymorphism in the transforming growth factor beta1 gene and breast cancer among elderly white women: The study of osteoporotic fractures
22. Site-dependent production of transforming growth factor beta1 in colonic mucosa: Its possible role in tumorigenesis of the colon
23. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis
24. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice
25. Somatic alterations of the DPC4 and Madr2 genes in colorectal cancers and relationship to metastasis
26. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities
27. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis
28. Molecular predictors of survival after adjuvant chemotherapy for colon cancer
29. Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis
30. Mitogenic conversion of transforming growth factor-beta1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer
31. Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III
32. Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: A mechanism leading to increased malignancy in epithelial cells
33. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells
34. Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta
35. Involvement of the Ras/MAPK signaling pathway in the modulation of urokinase production and cellular invasiveness by transforming growth factor-beta(1) in transformed keratinocytes
36. Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen- activated protein kinase
37. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells
38. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism
39. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration
40. Oncogenic ras represses transforming growth factor-beta/mad signaling by degrading tumor suppressor smad4
41. Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas
42. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway
43. Smads mediate signaling of the TGFbeta superfamily in normal keratinocytes but are lost during skin chemical carcinogenesis
44. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer
45. Smad7 is induced by CD40 and protects WEHI 231 B-lymphocytes from TGFbeta-induced growth inhibition and apoptosis
46. Ultraviolet irradiation blocks cellular responses to transforming growth factor-beta by down-regulating its type-II receptor and inducing Smad7
47. Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF
48. The two-handed E box binding zinc finger protein SIP1 downregulates E- cadherin and induces invasion
49. Functional cloning of the proto-oncogene brain factor-1 (BF-1) as a Smad-binding antagonist of transforming growth factor-beta signaling
50. Regulation of Smad signaling by protein kinase C
51. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling
52. The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway
53. Different sensitivity of the transforming growth factor-beta cell cycle arrest pathway to c-Myc and MDM-2
54. Expression of the telomerase catalytic subunit, hTERT, induces resistance to transforming growth factor beta growth inhibition in p16INK4A(-) human mammary epithelial cells
55. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis
56. TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system
57. Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer
58. A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats
59. Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia
60. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells
61. Captopril restores transforming growth factor-beta type II receptor and sensitivity to transforming growth factor-beta in murine renal cell cancer cells
62. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta
63. High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells